Effect of Platelet Rich Plasma on Post Cryopreservation Viability, Morphology and Proliferation of Human Umbilical Cord Stem Cells by Goei, Noviyanti et al.
  
© 2015 Noviyanti Goei, Isabella Kurnia Liem, Jeanne Adiwinata Pawitan and Dian Mediana. This open access article is 
distributed under a Creative Commons Attribution (CC-BY) 3.0 license. 




Original Research Paper 
Effect of Platelet Rich Plasma on Post Cryopreservation 
Viability, Morphology and Proliferation of Human Umbilical 





Isabella Kurnia Liem, 
3,5





1Biomedical Master Program, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia 
2Department of Anatomy, Faculty of Medicine, Universitas Trisakti, Jl. Kyai Tapa, Jakarta, Indonesia 
3Stem Cell Medical Technology Integrated Service Unit, Cipto Mangunkusumo Central Hospital,  
Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia 
4Department of Anatomy, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia 







Corresponding Author:  
Jeanne Adiwinata Pawitan  
Department of Histology, 
Faculty of Medicine, 
Universitas Indonesia, Jakarta, 
Indonesia 
Email: jeanneadiwip@gmail.com 
Abstract: In most cryopreservation medium, Fetal Bovine Serum (FBS) is 
used as supplement, while it is well known that FBS contains xenoproteins 
that can be incorporated into the cells and may be harmfull, as they can 
elicit immune response. Therefore, finding other xenofree materials as FBS 
alternative in cryopreservation medium is very important. Platelet Rich 
Plasma (PRP) is albumin rich and is a candidate for FBS alternative as 
cryopreservation supplement. Albumin is a natural extracellular 
cryoprotective agent that stabilizes impaired cell membrane during 
cryopreservation. This was an in vitro analytical study to to compare the 
effect of PRP and FBS as supplement in cryopreservation medium on 
human umbilical cord stem cells. In this study the stem cells were isolated 
from an umbilical cord tissue by explant method and propagated untill we 
got enough cells for cryopreservation. Cryopreservations were done using 
eight types of protocol, which differed in type and concentration of 
supplement and cell concentration. The effect of the eight protocols were 
compared in terms of post cryopreservation cell viability, morphology, cell 
size and proliferation. There were no difference between FBS and PRP 
supplemented cryopreservation media in term of cell viability and 
morphology. PRP supplemented medium showed better post 
cryopreservation performance in cell size and proliferation. PRP can be 
used as an alternative to FBS in cryopreservation medium for human 
umbilical cord tissue derived stem cells.  
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Introduction  
Stem cells are primitive cells that are endowed with 
self renewal capacity and can differentiate into other 
types of mature cells and thus is regarded as 
multipotent (Emil et al., 2005). Umbilical cord is a 
promising source of stem cells that have been 
attempted to cure various diseases since 1988. 
Umbilical cord as stem cell source has various 
advantages compared to other sources as it is easily 
collected from delivery waste, does not cause adverse 
effects to donor, devoid of ethical problems and the 
major advantage is its naive immune property, which 
may greatly reduce rejection problems (Goldstein et al., 
2007). Therefore, cryopreservation method is 
indispensable, if the stem cells are intended to be used 
for   autologous   or  allogeneic  cell therapy 
(Goldstein et al., 2007). However, there is no 
standardized cryopreservation method, especially for 
umbilical cord derived stem cells (Berz and Colvin, 2012).  
There are various protocols for cryopreservation, 
which differ in the type and concentration of 
supplement and in cell concentration. These variables 
may have effects on post cryopreservation cell 
viability, morphology and proliferation capacity, when 
the cells are cultured in vitro. Moreover, some 
protocols use xeno material as supplement that may 
cause immune response
 
(Mackensen et al., 2000) and 




stimulation of hapten formation (Martin et al., 2005).  
Therefore, finding xenofree supplement that is suitable 
for human umbilical cord derived stem cells is very 
important and platelet rich Platelet Rich Plasma (PRP) 
is a candidate (Pawitan, 2012). Murphy et al. (2012) 
found that PRP was an alternative supplement for 
murine cord blood derived mesenchymal stem cell 
cryopreservation. 
However, there was no standardized supplement 
concentration for cryopreservation medium, though 
some protocols used 10 or 20%. A study   compared 
fibroblast viability after cryopreservation using various 
FBS concentrations, i.e., 0, 10, 20, 50 and 80% and 
found that 50 and 80% FBS caused decreased viability 
Falanga et al. (2004). Another study compared 40 and 
70% FBS and found no significant difference in 
viability and recomended the use of 40% FBS 
(Nazarpour et al., 2012). 





(Falanga et al., 
2004; Simione, 2009; LTC, 2012; Meyer et al., 2006; 
Alencar et al., 2010; Rowley et al., 1994). Rowley et al. 
(1994) showed that a concentration of 5.6×10
8 
was 





 cellsl/mL and found no 
significant difference in viability. Meyer et al. (2006) 
showed that a concentration of 5×10
7
 gave 89% viability. 
Synth-a-Freeze®, (LTC, 2012) a commercial 
cryopreservation medium, recommends cell 
concentration 0.5-3×10
6 







Therefore, this study aimed to compare the effect of 
10 and 40% PRP and 10 and 40% FBS as supplement in 
cryopreservation medium on human umbilical cord stem 
cells, using two cell concentrations of 100.000 and 
500.000 cells/mL.   
Materials and Methods  
This was an experimental analytic in vitro study, 
which was done in Stem Cell Medical Technology 
Integrated Service Unit, Cipto Mangunkusumo Central 
Hospital-Faculty of Medicine Universitas Indonesia, 
from April through November 2014. This study got 
ethical aproval from the Ethical Commitee of the Faculty 
of Medicine, Universitas Indonesia (ethical clearance  
No.665/UN2.F1/ETIK/2014). Stem cells for this study 
were isolated using multiple harvest explant method
 
(Pawitan et al., 2014) from an umbilical cord that was 
obtained from a Caesarean section delivery, after the 
woman signed the informed consent form. The cells 
were propagated untill passage 1 and 2 to get enough 
cells for cryopreservation experiments and upon 
subculture would become passage 2 and 3. 
Comparison of Cryopreservation Protocols 
We compared eight protocols with variation in type 
of supplement (PRP and FBS), supplement concentration 
(10 and 40%) and cell concentration (100,000 and 
500,000 cells/mL). The eight protocols can be seen in 
Table 1. All protocols contained final concentrations of 
100U Penicillin/100 µg Streptomycin/mL (Biosera LM-
A4118/100) and 0.25 µg Fungizone/mL (Gibco 15290-
018) in αMEM (Gibco 12000-014) as basal medium and 
10% DMSO (Sigma D2650). The cells used were 
passage 1 and 2 cells with two replications each and 
therefore there were a total of 32 groups. 
Cryopreservation Procedure 
Cryopreservation was done by putting cell and 
cryopreservation medium containing cryotubes in-20°C 
for 24 h and then the cryotubes were transfered to -
196°C (in liquid nitrogen tank) for one month. After 
one month, the cryotubes were transfered to 37°C (in a 
water bath), to thaw the cells. Post thawed stem cells 
were checked for their viability and subcultured. 
Cultures of post thawed cells were compared to those 
of fresh cells. When the cells were 30% confluent, 
photographs were taken to observe their morphology 





using Axiocam measuring program. 
Further, viability at harvest and Population Doubling 
Time (PDT) was calculated. 
Data collection and Analysis 
Data collected were post thawing and after culture 
cell-viability, cell size and PDT. When the data were 
suitable for parametric test, the differences in cell 
viability, size and PDT of post thawed cells  between 
the eight protocols and fresh cells were analyzed using 
Analyses of Variance (ANOVA) from Statistical 
Product and Service Solution (SPSS) software version 
16. However, when the data were not suitable, Kruskal-
Wallist test was used. Data of pre and post thawing 
were compared by paired t test (for parametric data) or 
Wilcoxon signed rank test (for non parametric data).
 
Table 1. Various cryopreservation protocols 
Protocol 1(P10-100)  2(P10-500) 3(F10-100) 4(F10-500) 5(P40-100) 6(P40-500) 7(F40-100) 8(F40-500) 
Suppl  PRP 10% PRP 10% FBS 10% FBS 10% PRP 40% PRP 40% FBS 40% FBS 40% 
Cell C 100 500 100 500 100 500 100 500 
Suppl = Supplement, PRP = Platelet Rich Plasma, FBS = Fetal Bovine Serum, Cell C = Cell Concentration/mL (×1000) 




Data from passage two and three were compared by 
independent t test (for parametric data) or Mann-
Whitney test (for non parametric data). When there 
was a significant difference, post hoc test was done to 
locate the difference. 
Results  
Post thawing cell counts were greatly reduced, 
especially in 100,000 cell concentration protocols 
(protocol 1, 3, 5 and 7). Therefore, viability tests were 
done on available remaining cells in each protocols. 
Cell Viability 
The medians of pre and post thawing cell-viability 
were 95.17 and 81.81% respectively and Wilcoxon test 
showed significant difference with a median difference 
of 13.36%. However, Kruskal-Wallis test showed no 
significant difference in post thawing and after culture 
cell-viability between the eight protocols. 
Morphology and Cell Size 
Subcuture from fresh and post thawed cells of the 
eight protocols showed similar cell morphology that 
was fibroblastic (elongated and spindle shaped).  
Median of cell size after culture in passage-2 and 
passage-3 were 2464.5 µm
2
 and 2072.19 µm
2
 
respectively and Mann-Whitney test showed a 
significant difference, with a median difference of 
392.31 µm
2
. Moreover, Kruskal-Wallis test of cell 
size after culture between the eight protocols and fresh 
cells showed no significant difference in passage-3 
cells, but there were significant differences in passage-
2 cells between the eight protocols with fresh cells. Cell 
size of passage-2 cells after culture from the eight 
protocols and fresh cells can be seen in Fig. 1. 
Differences in cell size and p value between the eight 








Fig. 2. PDT after culture of the eight protocols and fresh cells 




Table 2.  p values of comparison of between fresh cell and the eight protocol cell size after culture of passage-2 cells 
Group A B C D E F G H I 
A  0,532*  0,001*  0,954*  0,453*  0,189** 0,718* 0,981* 0,004* 
  (135,83) (530,74) (59,89) (103,72) (261,2)* (116,17) (22,56) (482,14) 
B 0,532*  0,0001* 0,707* 0,836* 0,029* 0,312* 0,617* 0,002* 
 (135,83)  (666,57) (195,72) (32,11) (359,32) (252) (113,27) (617,97) 
C 0,001* 0,0001*  0,001* 0,0001* 0,077* 0,003* 0,002* 0,441* 
 (530,74) (666,57)  (470,85) (634,46) (307,25) (414,57) (553,3) (48,6) 
D  0,954* 0,707* 0,001*  0,665* 0,103* 0,637* 0,693* 0,004* 
 (59,89) (195,72) (470,85)  (163,61) (163,6) (56,28) (82,45) (422,25) 
E  0,453* 0,836* 0,001* 0,665*  0,025* 0,260* 0,336* 0,001* 
 (103,72) (32,11) (634,46) (163,61)  (327,21) (219,89) (81,16) (585,86) 
F 0,189* 0,029* 0,077* 0,103* 0,025*  0,197* 0,172* 0,277* 
 (261,2)* (359,32) (307,25) (163,6) (327, 21)  (107,32) (246,05) (258,65) 
G 0,718* 0,312* 0,003* 0,637* 0,260* 0,197*  0,832* 0,019* 
 (116,17) (252) (414,57) (56,28) (219,89) (107,32)  (138,73) (365,97) 
H 0,981* 0,617* 0,002* 0,693* 0,336* 0,172* 0,832*  0,020* 
 (22,56) (113,27) (553,3) (82,45) (81,16) (246,05) (138,73)  (504,7) 
I 0,004* 0,002* 0,441* 0,004* 0,001* 0,277* 0,019*, 0,020* 
 (428,14) (617,97) (48,6) (422,25) (285,86) (258,65) (365,97) (504,7) 
*= Mann- Whitney test, **=  independent t- test, ( )= cell size median diffeence, ( )*= cell size mean difference, A: PRP 10% and cell concentration 
100,000, B: PRP 10% and cell concentration 500,000, C: PRP 40% and cell concentration 100,000, D: PRP 40% and cell concentration 500,000, E: 
FBS 10% and cell concentration 100,000, F: FBS 10% and cell concentration 500,000, G: FBS 40% and cell concentration 100,000, H: FBS 40% and 
cell concentration 500,000, I: fresh cells 
 
Table 3.  p values of comparison of between fresh cell and the eight protocol   PDT after culture 
Group A B C D E F G H I 
A  0,363**  1,000*  0,126*  0,500*  0,062** 0,155** 0,268** 0,12* 
  (0,1) * (0,12) (0,15) (0) (0,2)* (0,2) (0,24) * (0,57) 
B 0,363**  0,680* 0,262* 0,186* 0,177** 0,378** 0,051** 0081* 
 (0,1) *  (0,03) (0,06) (0,09) (0,1) * (0,1) * (0,34) * 
C 1,000* 0,680*  0,376* 0,157* 0,160* 0,201* 0,483* 0,149* 
 (0,12) (0,03)  (0,03) (0,12) (0,08) (0,21) (0,21) (0,45) 
D  0,126* 0,262* 0,376*  0,015* 0,861* 0,934* 0,023* 0,106* 
 (0,15) (0,06) (0,03)  (0,15) (0,05) (0,18) (0,24) (0,42) 
E  0,500* 0,186* 0,157* 0,015*  0,006* 0,095* 0,867* 0,044* 
 (0) (0,09) (0,12) (0,15)  (0,2) (0,33) (0,09) (0,57) 
F 0,062** 0,177** 0,160* 0,861* 0,006*  0,981** 0,019** 0,153* 
 (0,2)* (0,1)* (0,08) (0,05) (0,2)  (0)* (0,44)* (0,37) 
G 0,155* 0,378* 0,201* 0,934* 0,095* 0,981**  0,118** 0,351* 
 (0,2)* (0,1)* (0,21) (0,18) (0,33) (0)*  (0,44)* (0,24) 
H 0,268** 0,051** 0,483* 0,023* 0,867* 0,019** 0,118**  0,021* 
 (0,24)* (0,34)* (0,21) (0,24) (0,09) (0,44)* (0,44) *  (0,66) 
I 0,12* 0,081* 0,149* 0,106* 0,044* 0,153* 0,351* 0,021* 
 (0,57) (0,48) (0,45) (0,42) (0,57) (0,37) (0,24) (0,66) 
*= Mann- Whitney test, **=  independent t- test, ( )= PDT median difference, ( )*= PDT mean difference, A: PRP 10% and cell concentration 100.000, 
B: PRP 10% and cell concentration 500.000, C: PRP 40% and cell concentration 100.000, D: PRP 40% and cell concentration 500.000, E: FBS 10% 
and cell concentration 100.000, F: FBS 10% and cell concentration 500.000, G: FBS 40% and cell concentration 100.000, H: FBS 40% and cell 
concentration 500.000, I: fresh cells 
 
Population Doubling Time 
The PDT after culture of the eight protocols and 
fresh cells can be seen in Fig. 2. Kruskal-Wallis test 
showed significant diffence in PDT after culture of 
the eight protocols and fresh cells. Differences in PDT 
and p value between the eight protocols and fresh 
cells can be seen in Table 3.  
Discussion 
In this study, there was a significant decrease 
(13.36%) in the median of pre and post thawing cell 
viability from 95.17 to 81.81%. Post thawing cell 
viability in this study was relatively higher compared to 
the study of  Polchow et al. 
 
(2012) which found that 
post thawing viability was not more than 70%. The 




difference might be due to different source of 
cryopreserved cell, as Polchow et al. (2012) used 
human vascular umbilical cord cells. Another study by 
Ginis et al. (2012) 
 
found post thawing cell viability of 
72 and 80% using 5 and 10% DMSO containing 
cryopreservation medium respectively, (Ginis et al., 2012) 
which was similar to our result.  
In this study, there was no significant difference in 
post thawing and after culture cell-viability between 
the protocols that used FBS and PRP. This fact 
suggests that  PRP is equivalent in preserving post 
thawing cell viability to FBS. 
In this study, after culture cell morphology for 
cryopreserved cells was fibroblastic (elongated and 
spindle shaped), similar to the findings of other studies  
(Polchow et al., 2012; Baksh et al., 2007; Secco et al., 
2008; Xiang et al., 2007). We did not find any clusters of 
cells with endothelial appearance/cobblestone like, 
which might be due to the cryopreserved cell source that 
were from passage-1 and passage-2. 
Morphology of cryopreserved cells using PRP and 
FBS supplement was similar and this result was in 
line with the findings of other studies (Polchow et al., 
2012; Xiang et al., 2007). This fact suggests that PRP 
is equivalent in preserving post thawing cell 
morphology to FBS. 
A study by Scheers et al. (2013) showed increase in 
cell size with increasing passage, which was supposed as 
cell aging and therefore it was suggested that small cells 
were preferable. However, there was no published study 
that measured cell size.  
Cryopreserved cell size after culture showed that 
cells from passage-3 were significantly smaller  
compared to those from passage-2, with a median 
difference of 392.31 µm. This fact might be due to 
increasing homogeneity with increasing passage, as 
was found by two studies on mesenchymal stem cells 
(Doan et al., 2012; Liem et al., 2014). 
Cryopreserved cell size after culture of protocol P40-
100 cells were significantly smaller compared to those of 
P10-500, P40-500, F10-100, F40-100 and F40-500 and 
this fact suggested that PRP 40% as supplement was 
better in preserving cryopreserved cell size after culture. 
Fresh cells from passage-2 were smaller compared 
cryopreserved cells of protocol P10-100, P10-500, P40-
500, F10-100, F40-100 and F40-500 after culture. This 
finding was different from Bahadori et al. (2009) 
findings that found cryopreserved MSC morphology 
after culture was similar until passage-9 and increase in 
size happened after passage-10, where the cells became 
flatten and large that indicated aging (Bahadori et al., 
2009). In this study, increase in cryopreserved cell size 
after culture might be due to the property of some viable 
cells from passage-2 that loss their ability to attach and 
proliferate, so that seeding of   5000 cells/cm
2
 was in fact 
far smaller and therefore needed more population 
doubling to become confluent. Moreover, cryopreserved 
cell concentration in Bahadori et al. (2009) study was 
10
6
 cellsl/mL that caused decrease in DMSO 
concentration at seeding compared to this study. 
In this study, increase in proliferation rate was in line 
with decrease in proliferation doubling time. 
Proliferation doubling time in protocol P40-500 that was 
smaller compared to those of F10-100 and F40-500 
showed that PRP 40% was better than FBS 40% and cell 
concentration of 500.000 was better than 100.000 in 
preserving cryopreserved cell proliferation.  
A study found no difference in proliferation rate 
between  cryopreserved  and  fresh  MSCs, 
(Vasconcelos et al., 2012) while another study found 
higher proliferation rate in cryopreserved compared to 
fresh cells that was supposed to be due to cell selection 
(Ginis et al., 2012).  In our study, PDT of fresh cells was 
significantly smaller compared to cryopreserved cells in 
protocol F10-100 and F40-500. Higher proliferation rate 
in fresh cells might be due to cryopreservetion injury 
that was endured by cryopreserved cells due to DMSO 
and very low cooling effect compared to fresh cells that 
were relatively intact (Gao and Critser, 2000).  
Lower proliferation rate of cryopreserved cells in 
this study might be due to our cryopreservation 
procedure that did not use slow cooling method. In our 
study, we put the cell and cryopreservation medium 
containing cryotubes in -20°C for 24 h and then the 
cryotubes were directly transfered to -196°C,  while 
other studies used slow cooling method (Ginis et al., 
2012; Vasconcelos et al., 2012). 
Greatly reduced cell number after washing step after 
thawing may cause problems, if cryopreservation is 
intended to keep the cells for later use. Moreover, too 
low cell count might cause bias in viability testing and 
this fact was the limitation of our study. 
Conclusion  
Platelet rich plasma can be used as FBS substitute in 
cryopreservation medium and the use of PRP 40% and 
higher cell concentration is recommended.  
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